ABSTRACT. Quantitative fluorescent polymerase chain reaction (QF-PCR), in recent years, has been accepted as a rapid, high throughput, and sensitive method for prenatal diagnosis of common chromosomal aneuploidies. Since short tandem repeats (STRs) are the cornerstone of QF-PCR technique, selection of the most polymorphic STR markers is an essential step for a successful QF-PCR assay. The genetic variation parameters of each STR marker differ among different populations. In this study, we investigated the size, frequency, heterozygosity, polymorphism information content, power of discrimination, and other genetic polymorphism data for 21 STR markers on chromosomes 13, 18, 21, X, and Y in 1000 amniotic fluid samples obtained from south Iranian women. Our results showed that all the 21 STR markers are highly polymorphic and informative in our population. The heterozygosity, polymorphism information content, and power of discrimination of the markers were 62-91.1%, 0.61-0.91, and 0.830-0.976, respectively. The locus D18S386 was the most polymorphic STR, while the locus DXYS218 was the least polymorphic STR among all the studied STRs. The present study has provided extensive data regarding the efficiency of the 21 STR markers for diagnosis of chromosomes 13, 18, 21, X, and Y aneuploidies in the south Iranian population.
INTRODUCTION
The most common prenatally diagnosed abnormalities are aneuploidies such as trisomy 21 (Down syndrome), trisomy 18 (Edward syndrome), trisomy 13 (Patau syndrome), and sex chromosome aneuploidies (Divane et al., 1994) . It has been estimated that 5% of all human conceptions are aneuploidy (Hassold and Hunt, 2001) . Despite the efficiency of karyotyping as a gold standard technique (Shaffer and Bui, 2007) , quantitative fluorescent polymerase chain reaction (QF-PCR) has emerged as a rapid, accurate, cost effective, and high throughput method for prenatal diagnosis of chromosomal aneuploidies (Cirigliano et al., 2006; Mann et al., 2008; Mann and Ogilvie, 2012; Rostami et al., 2015) . QF-PCR is a PCR-based technique that amplifies short tandem repeats (STRs) located on chromosomes of interest to determine the copy numbers of those chromosomes present per cell (Langlois and Duncan, 2011) . STR markers are highly polymorphic repetitive sequences distributed throughout the genome of eukaryotes with a low mutation rate (Tóth et al., 2000) . These abovementioned characteristics explain the wide application of STRs in forensic individual identification, prenatal and postnatal diagnosis of chromosome aneuploidies, and paternity testing (Mansfield, 1993) . STR markers demonstrating two peaks are heterozygote and are known as informative markers and those demonstrating only one peak are homozygote and are known as uninformative markers (Andonova et al., 2004; Quaife et al., 2004) . In order to perform a reliable and accurate QF-PCR assay, a minimum of two heterozygote markers per chromosome are required to confirm the copy number of the chromosome of interest (Association for Clinical Cytogenetics and Clinical Molecular Genetics Society, 2012). Consanguineous marriages result in decreased heterozygosity and informativeness of STR markers (Choueiri et al., 2006) . Hence, for populations with a higher degree of consanguinity, evaluating the polymorphisms and heterozygosity of STRs is an essential step before applying QF-PCR (Lee et al., 2010; Jain et al., 2012) . The aims of this study were to evaluate the genetic variation parameters of 21 STR markers for detection of common chromosomal aneuploidies in the south Iranian population. Here, we represented the genetic variations and population data of 1000 amniotic fluid samples and compared our findings with those obtained for data from other populations. To the best of our knowledge, no data for these STR markers are currently available for our population.
MATERIAL AND METHODS

Sample collection
Amniotic fluid (AF) samples (N = 1000) were collected from women, at an increased risk of chromosomal abnormalities, in the first or second trimester screening programs referred to Comprehensive Medical Genetic Center (Shiraz, Iran) from March 2014 to June 2015. Informed consent for sample collection and consequent analysis was obtained from all contributors. The samples were divided into two parts, for genomic extraction followed by QF-PCR and cytogenetic diagnosis (karyotyping) as a confirmatory test.
DNA extraction
The "salting out protocol" was carried out according to the manufacturer's guidelines (RIBO-prep, Moscow, Russia). Briefly, 1 to 2 mL AF sample was centrifuged (Eppendorf, Sigma, St. Louis, MO, USA) at 10,416 g for 10 min. After discarding the supernatant, 100 µL prepared samples were mixed thoroughly with 300 µL solution for lysis by vortexing. The tubes were centrifuged for additional 5 s to ensure that there were no residual drops left on the cap; then, the samples were incubated in a 65°C water bath for 5 min. Precipitation solution (400 µL) was added and mixed with the samples by vortexing. The samples were centrifuged at 14,549 g in a bench top centrifuge for 5 min, and the supernatant was discarded carefully without disturbing the pellet. After pellet washing steps, all the tubes were incubated at 65°C for 5 min with open caps (to dry the pellet). Buffer (30 µL) was added to each tube and mixed with the pellet by vortexing, followed by incubation at 65°C for 5 min with occasionally stirring by vortex. Concentration of the extracted DNA was determined by ultraviolet absorbance measurement at 260 nm using the NanoDrop Lite spectrophotometer (Thermo Scientific, USA).
PCR
Devyser Extend v2 (Hägersten, Sweden) aneuploidy detection kit was used for the amplification of 21 STR markers on chromosomes 13, 18, 21, X, and Y in each tube. In general, PCR amplification was carried out in a 25-µL total volume by adding 20 µL prepared PCR mix containing Hot Start Taq polymerase to the extracted genomic DNA (3-30 ng). After activation of the enzyme at 95°C for 15 min, 27 cycles were applied according to the manufacturer instructions using Veriti thermal cycler (Applied Biosystems, Foster City, CA, USA).
Capillary electrophoresis
Fragment analysis of the PCR products were performed by Applied Biosystems 3500 Genetic Analyzer (Applied Biosystems), using the 3500 Data Collection software, 50 cm capillary array length, and Performance Optimized Polymer 7 (Applied Biosystems) for electrophoresis. In brief, each amplified sample (1.5 µL) was added to 15 µL ultrapure HiDi formamide (Applied Biosystems) and 0.3 µL size standard LIZ 500 (GeneScan, Applied Biosystems) on a MicroAmp optical 96-well reaction plate (Applied Biosystems). Prior to electrophoresis, the mixture was heated for 5 min at 95°C for denaturation. Data were analyzed and electropherograms were made using the Gene Mapper ID software v3.2.
Genetic variation analysis
Heterozygosity, typical paternity index, polymorphism information content (PIC), power of exclusion (PE), probability of identity (matching probability), and power of discrimination (PD) were calculated using the PowerStatsv12 software (Promega Corp., Madison, WI, USA).
RESULTS
Allelic size
The study was performed on 1000 AF samples. The observed allelic sizes for each STR marker are shown in Table 1 . Minor differences can be seen between the observed and expected allelic sizes, and most of the observed allelic sizes were narrower than the expected sizes. 352, 356, 360, 364, 368, 372, 376, 380, 384, 388, 392, 396, 400, 404, 408, 412 D18S976 18p11.31 440-495 448-476 448, 450, 452, 454, 458, 460, 462, 464, 466, 468, 472, 476 GATA178F 18p11.32 350-410 368-396 368, 370, 372, 376, 380, 384, 388, 392, 396 D13S742 13q12.12 222-334 235-295 235, 249, 253, 255, 257, 261, 265, 269, 271, 273, 275, 279, 283, 285, 295 D13S634 13q21.32-q21.33 365-435 392-416 392, 396, 400, 402, 404, 406, 408, 410, 412, 414, 416 D13S628 13q31.1 420-475 432-468 432, 440, 444, 448, 452, 456, 460, 464, 468 D13S305 13q13.3 435-505 436-476 436, 444, 448, 452, 456, 460, 464, 468, 472, 476 D13S1492 13q21.1 100-175 104-160 104, 112, 116, 120, 124, 128, 132, 136, 140, 144, 148, 152, 156, 160 D21S1435 21q21.3 150-208 171-195 171, 175, 179, 183, 187, 191, 195 D21S1411 21q22.3 245-345 261-335 261, 275, 285, 289, 293, 297, 301, 305, 307, 309, 311, 313, 315, 317, 319, 323, 327, 331, 335 D21S1444 21q22.13 440-495 455-483 455, 459, 463, 467, 471, 475, 479, 483 D21S1442 21q21.3 362-420 373-405 373, 377, 381, 385, 389, 393, 397, 401, 405 D21S1437 21q21.1 105-152 113-149 113, 117, 121, 125, 129, 133, 137, 141, 145, 149 D21S11 21q21.1 215-290 235-269 235, 239, 243, 247, 251, 253, 257, 261, 265, 269 DXS1187 Xq26.2 120-170 131-155 131, 133, 135, 139, 143, 147, 151 
Allelic frequency
The frequency of each allele was calculated for all 21 STR markers and the results are shown in Figure 1 and Tables S1 and S2. The most frequent alleles in our population for D13S742 marker were 257-bp (16%), 261-bp (14%), and 269-bp (13%) alleles; D13S634 marker, 400-bp allele (19%); D13S628 marker, 456-bp allele (39%); D13S305 marker, 468-bp allele (27%); and for D13S1492 marker, 136-bp allele (19%) ( Figure 1A ). As shown in Figure 1B , the most frequent alleles for D18S535 marker were 321-and 329-bp alleles (27%); D18S978 marker, 212-bp (34%) and 216-bp (29%) alleles; D18S386 marker, 368-bp (15%) and 396-bp (12%) alleles; D18S976 marker, 458-bp allele (33%); and for GATA178F marker, 380-bp allele (25%). As shown in Figure 1C , the most frequent allele for D21S1435 marker was 183-bp allele (39%); D21S1411 marker, 301-bp (18%), 297-bp (15%), and 305-bp (13%) alleles; D21S1444 marker, 467-bp allele (33%); D21S1442 marker, 389-bp allele (24%); D21S1437 marker, 133-bp allele (33%); and for D21S11 marker, was 247-bp allele (26%). As shown in Figure 1D , the most frequent allele for DXS1187 marker was 147-bp allele (29%); XHPRT marker, 286-and 290-bp alleles (34%); DXS2390 marker, 335-bp allele (29%); for DXS267 marker, 195-bp allele (46%); and for DXS218 marker, 243-bp allele (46%). 
Genetic variation parameters
In this study, heterozygosity and other genetic variation parameters were calculated for evaluating the polymorphism quality of 21 STR markers (Table 2 ). All 21 STR markers displayed acceptable polymorphism and heterozygosity in our population. Heterozygosity, PIC, and PD were 62-91.1%, 0.61-0.91, and 0.830-0.976, respectively. Among all the STR markers, D18S386, D13S742, D21S1411, D21S1437, D21S11, D13S305, and D13S1492 showed the highest heterozygosity of more than 80%, with heterozygosity of 91.1, 89.1, 88, 88, 84.2, 83.2, and 81.8%, respectively. DXYS218, DXYS267, and D21S1435 STRs showed the least heterozygosity, with heterozygosity of 62, 70, and 70.1%. According to the results obtained for heterozygosity and PIC of each of the 21 STR markers, the locus D18S386 was the most polymorphic marker and DXYS218 was the least polymorphic marker. 
DISCUSSION
The QF-PCR assay is a widely used clinical assay owing to its high sensitivity and specificity and is now performed routinely in the majority of prenatal centers worldwide (Andonova et al., 2004; Onay et al., 2008; Putzova et al., 2008) . In order to achieve conclusive results in a QF-PCR aneuploidy detection assay, selection of the most heterogeneous STR markers is the key step. Since the informativeness of STR markers is a population-dependent factor, it is recommended that markers should be evaluated for a particular population. Aneufast (Wollerau, Switzerland), ChromoQuant (Solna, Sweden), and Devyser are among the most popular QF-PCR aneuploidy detection kits for prenatal diagnosis of aneuploidies. A limitation of the aforementioned kits is that these are designed for populations of European-descent; hence, they may be inefficient for other populations. There have been studies that evaluated the efficiency of Aneufast and ChromoQuant kits and assessed the STR markers they employed (Cirigliano et al., 2009; Nasiri et al., 2011) , but no publication that has evaluated all the STR markers applied in Devyser QF-PCR kit. In this study, we validated all the STR markers used in the Devyser commercial kit and could provide extensive data on them due to the sample size of 1000. Compared to the results obtained in studies by Mann et al. (2001 Mann et al. ( , 2008 , our results showed major heterozygosity differences between UK and Iranian study population. The heterozygosity of D18S535, D13S634, D21S1435, D21S1411, D21S1437, D21S11, XHPRT, and DXYS267 markers in the south Iranian population was lower than that in study populations reported by Mann et al. (2001 (Table 3 ). The heterozygosity reported by Mann et al. (2001 for D18S978, D18S386, D13S742, D13S628, D13S305, and DXS1187 markers was lower than that observed in the south Iranian population (Table  3) . Interestingly, some previously mentioned markers (D18S535, D21S1411 and D21S11, D18S978, D13S742, D13S628, and D13S305) showed heterozygosity results similar to those reported by Moftah et al. (2013) in Germany (Table 3 ). The heterozygosity of D18S535 and D21S1411 markers was similar to that observed in the Lebanese population (Choueiri et al., 2006) and the heterozygosity of D18S535, D13S634, and D21S11 was similar to that reported by Bili et al. (2002) in the Greek population (Table 3 ). Our findings showed that the heterozygosity rates of STR markers are different for different populations. Although we found that all 21 STR markers included in this study possess an acceptable rate of informativeness, the number of STR markers was limited, and there might be STRs with higher heterozygosity and polymorphisms in our population. This study is the first report on genetic variation data for the 21 STR markers in the south Iranian population. 
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